Related Experiment Video
Updated: May 23, 2025
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
5.5K
Neoadjuvant Treatment in Rectal Cancer
Srinath Bhradwaj R1, Aditya Sarin2, Shyam Aggarwal2
1Department of Medical Oncology, Apollo Cancer Institutes, Hyderabad, Telangana, India.
South Asian Journal of Cancer
|March 10, 2025
Summary
Total neoadjuvant therapy (TNT) improves rectal cancer outcomes by enhancing local responses and reducing systemic relapses. This approach shows promise for nonoperative management in patients achieving a clinical complete response.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Short-course radiotherapy and long-course chemoradiotherapy are established treatments for rectal cancer, improving local outcomes.
- Total neoadjuvant therapy (TNT) represents a significant advancement, offering enhanced local responses and reduced systemic relapse rates.
Purpose of the Study:
- To review the evidence supporting Total Neoadjuvant Therapy (TNT) in rectal cancer management.
- To discuss the details and implications of four key TNT trials.
Main Methods:
- Review of pivotal clinical trials investigating Total Neoadjuvant Therapy (TNT) for rectal cancer.
- Analysis of data regarding local outcomes, systemic relapse, and overall survival in TNT arms.
Main Results:
- TNT significantly improves local response rates compared to standard neoadjuvant chemoradiotherapy.
- TNT demonstrates a reduction in systemic relapse rates, contributing to improved overall survival.
- Four major TNT trials provide robust evidence for its efficacy.
Conclusions:
- Total Neoadjuvant Therapy (TNT) offers superior outcomes in rectal cancer management.
- TNT facilitates a higher rate of clinical complete responses, paving the way for nonoperative management strategies.
- The findings support the integration of TNT into standard rectal cancer treatment protocols.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
134
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
134
01:21Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
01:21Inflammatory Bowel Disease V: Surgical Management
80
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
80
01:29Drugs for Treatment of Ulcerative Colitis in IBD
116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171
01:26Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
39
Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
39